LaserSight's LaserScan 2000/LSX
This article was originally published in The Gray Sheet
Executive Summary
PMA is submitted for the scanning excimer laser platform. Data in support of the PMA were derived from a multicenter study evaluating use of the device to perform photorefractive keratectomy for treatment of myopia (nearsightedness) between -1.5 diopters and -10 D with less than or equal to 1 D astigmatism. LaserSight reports 1997 revenues (ended Dec. 31) of $24.4 mil, up 13% over 1996. Fourth-quarter revenues were flat at $6.3 mil. The company sells 13 laser systems in the fourth quarter, raising to 200 the total number of laser units sold to date
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: